A Tumor Microenvironments‐Adapted Polypeptide Hydrogel/Nanogel Composite Boosts Antitumor Molecularly Targeted Inhibition and Immunoactivation (Adv. Mater. 21/2022)

Abstract

Sequential Drug Delivery In article number 2200449, Di Li, Jianxun Ding, Tianmeng Sun, and co‐workers develop a tumormicroenvironments‐adapted gel composite for sequential drug release to reverse the epithelial–mesenchymal transition of tumor cells and regulate the tumor immune microenvironments, thereby inhibiting tumor growth and metastases. This process is like a painter using a paintbrush to turn a depressed and cold winter into a colorful and vibrant spring.

Biodegradable NIR‐II Pseudo Conjugate Polymeric Nanoparticles Amplify Photodynamic Immunotherapy via Alleviation of Tumor Hypoxia and Tumor‐Associated Macrophage Reprogramming

“…It is worth mentioning that the addition of Reg may facilitate the generation of ROS resulting from PDT. [ 29 ] Likewise, similar results can be obtained in K7M2 cells by FCM (Figure S7A,B, Supporting Information).…”

“…Based on the excellent immunomodulatory properties of Reg, [ 22,23,29,30 ] NP‐PDT@Reg nanoparticles with Reg were believed to reprogram TAMs. To verify the ability of NP‐PDT@Reg + L to repolarize M2 macrophages to the M1 phenotype, nanoparticles were added to interleukin‐4 (IL‐4)‐pretreated RAW264.7 macrophages (M2‐RAW264.7).…”

Progress in the preparation of Prussian blue-based nanomaterials for biomedical applications

“…Hydrogels typically exist in the form of gels, injectable gels, microgels and nanogels. [155][156][157] Gels are often used in wound dressings, vascular stents, tissue adhesion, and cardiac patches in the biomedical field. [158][159][160][161] Injectable hydrogels are also used as carriers to load drugs for sustained and controlled drug release, targeted release, or loaded with nanoparticles for diagnosis and treatment of tumors.…”

Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics

“…For example, Li et al have developed a polypeptide complex consisting of a thermoresponsive hydrogel (Gel, methoxy poly(ethylene glycol)-blockpoly(L-alanine)(mPEG-b-PAla)) and a ROS-responsive nanogel poly(N(ε)-benzyloxycarbonyl-L-lysine) (Gel/NG) as a carrier to deliver regorafenib (REG) and transforming growth factor-β inhibitor (LY3200882, LY) for both subcutaneous and orthotopic colorectal cancer therapy (Figure 6a). 160 mPEG-b-PAla was found to quickly undergo a phase transition from liquid to gel states at a temperature above 20 °C and thus was suitable for in vivo implantation (Figure 6c). The authors utilized this gel to create a sustained-drug-release platform, namely, Gel/(REG +NG/LY), that encapsulated REG and NG/LY.…”